检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:杨柳明[1] 吴志荣[1] 王华[1] 石贵明[1] 莫李生[1] 王丽峰[1] 林济宝 孔天翰[2]
机构地区:[1]广东省廉江市人民医院中西医结合研究所,廉江524400 [2]河南医科大学生物毒素中心,郑州450052
出 处:《河南医科大学学报》2001年第6期666-668,共3页Journal of Henan Medical University
基 金:广东省中医药管理局 1999立项课题 0 9946 7
摘 要:目的 :探讨痹痛灵治疗活动期类风湿病的临床效果。方法 :6 4例活动期类风湿性关节炎患者分别采用痹痛灵胶囊 (BTL)治疗 (治疗组 )及氨甲喋呤 (MTX) (对照组 )治疗。结果 :治疗 1个月 ,治疗组患者其晨僵、关节疼痛、及关节功能障碍等主要症状与体征均较治疗前显著改善 (P <0 .0 1或P <0 .0 5 ) ;而对照组则无明显改善 ,2组比较差异有显著性 (P <0 .0 1或P <0 .0 5 ) ;治疗 3个月 ,上述主要症状与体征 ,2组均较前有明显改善 (P <0 .0 1或P <0 .0 5 ) ;但治疗组优于对照组。ESR ,RF ,IgA ,IgG等炎性及免疫指标治后 2组较治前明显下降 (P <0 .0 1或P <0 .0 5 ) ;治疗组总有效率为 92 % ;对照组总有效率为 83% ,治疗组疗效优于对照组 (P <0 .0 5 )。结论 :痹痛灵胶囊改善类风湿患者症状与体征 ,控制急性炎性反应优于对照组 ;Aim: To probe into the clinical effects of bitongling capsule (BTL)on rheumatoid arthritis at active phase. Methods: A total of 64 patients with rheumatoid arthritis at active phase were divided into BTL treatment group(BTLG) and methorexate treatment group(MTXG). Results: After 1 month treatment,symptoms and signs,such as morning stiff ,arthralgia and articular dyskinesia of patients in BTLG improved significantly ( P<0.01 or P <0.05),while those of patients in MTXG did not and there was significant difference between these 2 groups( P <0.01 or P <0.05);After 3 month treatment,these symptoms and signs improved in both groups( P <0.01 or P <0.05),but BTLG had a better effect than MTXG.ESR,RF,IgG A and IgA decreased significantly in both groups after treatment( P <0.01 or P <0.05),while C 3 rose than before ( P <0.01 );the total response rate was 94.4% in BTLG higher than 83% in MTXG ( P <0.05).Conclusion: It is indicated that BTL can improve symptoms and signs of patients with RA and has better and faster effects on acute phase reaction than MTX;it has antiimmunologic effects similar to MTX,and has no obvious side effect.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.117